Literature DB >> 34413958

Rapid Evaluation of Small Molecule Cellular Target Engagement with a Luminescent Thermal Shift Assay.

Jonathan D Mortison1, Ivan Cornella-Taracido1, Gireedhar Venkatchalam2, Anthony W Partridge2, Nirodhini Siriwardana1, Simon M Bushell1.   

Abstract

Determination of target engagement for candidate drug molecules in the native cellular environment is a significant challenge for drug discovery programs. The cellular thermal shift assay (CETSA) has emerged as a powerful tool for determining compound target engagement through measurement of changes to a protein's thermal stability upon ligand binding. Here, we present a HiBiT thermal shift assay (BiTSA) that deploys a quantitative peptide tag for determination of compound target engagement in the native cellular environment using a high throughput, plate-based luminescence readout. We demonstrate that BiTSA can rapidly assess cellular target engagement of small molecule ligands against their cognate targets and highlight two applications of BiTSA for differentiating small molecules targeting mutant KRAS and TP53.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34413958      PMCID: PMC8366000          DOI: 10.1021/acsmedchemlett.1c00276

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  28 in total

1.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Authors:  Paul Morgan; Piet H Van Der Graaf; John Arrowsmith; Doug E Feltner; Kira S Drummond; Craig D Wegner; Steve D A Street
Journal:  Drug Discov Today       Date:  2011-12-29       Impact factor: 7.851

2.  Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.

Authors:  Shuo Chen; Jia-Le Wu; Ying Liang; Yi-Gang Tang; Hua-Xin Song; Li-Li Wu; Yang-Fei Xing; Ni Yan; Yun-Tong Li; Zheng-Yuan Wang; Shu-Jun Xiao; Xin Lu; Sai-Juan Chen; Min Lu
Journal:  Cancer Cell       Date:  2020-12-24       Impact factor: 31.743

3.  The cellular thermal shift assay for evaluating drug target interactions in cells.

Authors:  Rozbeh Jafari; Helena Almqvist; Hanna Axelsson; Marina Ignatushchenko; Thomas Lundbäck; Pär Nordlund; Daniel Martinez Molina
Journal:  Nat Protoc       Date:  2014-08-07       Impact factor: 13.491

4.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

5.  Importance of Quantifying Drug-Target Engagement in Cells.

Authors:  Jakub Stefaniak; Kilian V M Huber
Journal:  ACS Med Chem Lett       Date:  2020-03-06       Impact factor: 4.345

6.  Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.

Authors:  William T McElroy; Zheng Tan; Ginny Ho; Sunil Paliwal; Guoqing Li; W Michael Seganish; Deen Tulshian; James Tata; Thierry O Fischmann; Christopher Sondey; Hong Bian; Loretta Bober; James Jackson; Charles G Garlisi; Kristine Devito; James Fossetta; Daniel Lundell; Xiaoda Niu
Journal:  ACS Med Chem Lett       Date:  2015-05-12       Impact factor: 4.345

7.  SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.

Authors:  Mark Demma; Eugene Maxwell; Robert Ramos; Lianzhu Liang; Cheng Li; David Hesk; Randall Rossman; Alan Mallams; Ronald Doll; Ming Liu; Cynthia Seidel-Dugan; W Robert Bishop; Bimalendu Dasmahapatra
Journal:  J Biol Chem       Date:  2010-02-02       Impact factor: 5.157

8.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

Authors:  Matthew R Janes; Jingchuan Zhang; Lian-Sheng Li; Rasmus Hansen; Ulf Peters; Xin Guo; Yuching Chen; Anjali Babbar; Sarah J Firdaus; Levan Darjania; Jun Feng; Jeffrey H Chen; Shuangwei Li; Shisheng Li; Yun O Long; Carol Thach; Yuan Liu; Ata Zarieh; Tess Ely; Jeff M Kucharski; Linda V Kessler; Tao Wu; Ke Yu; Yi Wang; Yvonne Yao; Xiaohu Deng; Patrick P Zarrinkar; Dirk Brehmer; Dashyant Dhanak; Matthew V Lorenzi; Dana Hu-Lowe; Matthew P Patricelli; Pingda Ren; Yi Liu
Journal:  Cell       Date:  2018-01-25       Impact factor: 41.582

9.  Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.

Authors:  Åsa Fransson; Daria Glaessgen; Jessica Alfredsson; Klas G Wiman; Svetlana Bajalica-Lagercrantz; Nina Mohell
Journal:  J Ovarian Res       Date:  2016-05-14       Impact factor: 4.234

10.  The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors:  Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen
Journal:  Cancer Discov       Date:  2019-10-28       Impact factor: 38.272

View more
  1 in total

Review 1.  Current Advances in CETSA.

Authors:  Tuomas Aleksi Tolvanen
Journal:  Front Mol Biosci       Date:  2022-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.